CEL-SCI (NYSEMKT: CVM)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
CEL-SCI Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
CEL-SCI Company Info
The Company engages in the research and development of drugs and vaccines. Its most advanced product, Multikine, manufactured using the Companys proprietary cell culture technologies, is being developed for the treatment of cancer.
News & Analysis
The company attempted to clarify "confusion" related to its recent late-stage clinical results.
Everything went the wrong way for Cel-Sci.
Big news is coming for CEL-SCI, and we don't know which way the stock will move.
Who has the upper ground in a war between investors and short-sellers about whether a biotech's clinical trial for treating head and neck cancer can succeed?
These stocks were huge winners last week. But can their momentum continue?
Our investing community's latest pick to avoid: Vical.
More on investing in "baby biotechs."
Finally, a phase 3 trial for cancer therapy Multikine.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.